|
1.
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, et al: Effects of radiotherapy with concomitant
and adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.
|
|
2.
|
Gravendeel LA, Kouwenhoven MC, Gevaert O,
de Rooi JJ, Stubbs AP, et al: Intrinsic gene expression profiles of
gliomas are a better predictor of survival than histology. Cancer
Res. 69:9065–9072. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, et al: Integrated genomic analysis identifies clinically
relevant subtypes of glioblastoma characterized by abnormalities in
PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17:98–110. 2010.
View Article : Google Scholar
|
|
4.
|
Henrich KO, Schwab M and Westermann F:
1p36 tumor suppression - a matter of dosage? Cancer Res.
72:6079–6088. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Zlatescu MC, TehraniYazdi A, Sasaki H,
Megyesi JF, Betensky RA, Louis DN, et al: Tumor location and growth
pattern correlate with genetic signature in oligodendroglial
neoplasms. Cancer Res. 61:6713–6715. 2001.
|
|
6.
|
Lin N, Di C, Bortoff K, Fu J, Truszkowski
P, Killela P, Duncan C, McLendon R, Bigner D, Gregory S and Adamson
DC: Deletion or epigenetic silencing of AJAP1 on 1p36 in
glioblastoma. Mol Cancer Res. 10:208–217. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Aoki T, Hashimoto N and Matsutani M:
Management of glioblastoma. Expert Opin Pharmacother. 8:3133–3146.
2007. View Article : Google Scholar
|
|
8.
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, et al: Mirimanoff Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Salvati M, D’Elia A, Formichella AI and
Frati A: Insights into pharmacotherapy of malignant glioma in
adults. Expert Opin Pharmacother. 10:2279–2290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Giese A, Bjerkvig R, Berens ME and
Westphal M: Cost of migration: invasion of malignant gliomas and
implications for treatment. J Clin Oncol. 21:1624–1636. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Kitange GJ, Carlson BL, Schroeder MA,
Grogan PT, Lamont JD, Decker PA, Wu W, James CD and Sarkaria JN:
Induction of MGMT expression is associated with temozolomide
resistance in glioblastoma xenografts. Neuro Oncol. 11:281–289.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Frosina G: DNA repair and resistance of
gliomas to chemotherapy and radiotherapy. Mol Cancer Res.
7:989–999. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Oliva CR, Nozell SE, Diers A, McClugage
SG, et al: Acquisition of temozolomide chemoresistance in gliomas
leads to remodeling of mitochondrial electron transport chain. J
Biol Chem. 285:39759–39767. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Marcar L, Maclaine NJ, Hupp TR and Meek
DW: Mage-A cancer/testis antigens inhibit p53 function by blocking
its interaction with chromatin. Cancer Res. 70:10362–10370. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Monte M, Simonatto M, Peche LY, Bublik DR,
Gobessi S, Pierotti MA, Rodolfo M and Schneider C: MAGE-A tumor
antigens target p53 transactivation function through histone
deacetylase recruitment and confer resistance to chemotherapeutic
agents. Proc Natl Acad Sci. 103:11160–11165. 2006. View Article : Google Scholar
|
|
16.
|
Yang B, O’Herrin SM, Wu J, Reagan-Shaw S,
Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, Peng
H, Ivanov AV, Simpson AJ and Longley BJ: MAGE-A, MAGE-B, and MAGE-C
proteins form complexes with KAP1 and suppress p53-dependent
apoptosis in MAGE-positive cell lines. Cancer Res. 67:9954–9962.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Bhan S, Negi SS, Shao C, Glazer CA, Chuang
A, Gaykalova DA, Sun W, Sidransky D, Ha PK and Califano JA: BORIS
binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3,
and MAGEA4, is associated with their transcriptional activation in
lung cancer. Clin Cancer Res. 17:4267–4276. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Glazer CA, Smith IM, Bhan S, Sun W, Chang
SS, Pattani KM, Westra W, Khan Z and Califano JA: The role of
MAGEA2 in head and neck cancer. Arch Otolaryngol Head Neck Surg.
137:286–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Nardiello T, Jungbluth AA, Mei A,
Diliberto M, Huang X, Dabrowski A, Andrade VC, Wasserstrum R, Ely
S, Niesvizky R, Pearse R, Coleman M, Jayabalan DS, Bhardwaj N, Old
LJ, Chen-Kiang S and Cho HJ: MAGE-A inhibits apoptosis in
proliferating myeloma cells through repression of Bax and
maintenance of survivin. Clin Cancer Res. 17:4309–4319. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Sawada M, Nakashima S, Banno Y, Yamakawa
H, Hayashi K, Takenaka K, Nishimura Y, Sakai N and Nozawa Y:
Ordering of ceramide formation, caspase activation, and Bax/Bcl-2
expression during etoposide-induced apoptosis in C6 glioma cells.
Cell Death Differ. 7:761–772. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Tanaka K, Asanuma M and Ogawa N: Molecular
basis of anti-apoptotic effect of immunophilin ligands on hydrogen
peroxide-induced apoptosis in human glioma cells. Neurochem Res.
29:1529–1536. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Stegh AH, Chin L, Louis DN and DePinho RA:
What drives intense apoptosis resistance and propensity for
necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional
cell death regulator. Cell Cycle. 7:2833–2839. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Shore EM and Nelson WJ: Biosynthesis of
the cell adhesion molecule uvomorulin (E-cadherin) in Madin-Darby
canine kidney epithelial cells. J Biol Chem. 266:19672–19680.
1991.PubMed/NCBI
|
|
24.
|
Bharti S, Handrow-Metzmacher H,
Zickenheiner S, Zeitvogel A, Baumann R and Starzinski-Powitz A:
Novel membrane protein shrew-1 targets to cadherin-mediated
junctions in polarized epithelial cells. Mol Biol Cell. 15:397–406.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Gottardi CJ and Peifer M: Terminal regions
of beta-catenin come into view. Structure. 16:336–338. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Lilien J and Balsamo J: The regulation of
cadherin-mediated adhesion by tyrosine
phosphorylation/dephosphorylation of β-catenin. Curr Opin Cell
Biol. 17:459–465. 2005.PubMed/NCBI
|
|
27.
|
Castellone MD, Teramoto H, Williams BO,
Druey KM and Gutkind JS: Prostaglandin E2 promotes colon cancer
cell growth through a Gs-axin-beta-catenin signaling axis. Science.
310:1504–1510. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Liu X, Rubin JS and Kimmel AR: Rapid
Wnt-induced changes in GSK3beta associations that regulate
beta-catenin stabilization are mediated by Galpha proteins. Curr
Biol. 15:1989–1997. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Hino S, Tanji C, Nakayama KI and Kikuchi
A: Phosphorylation of β-catenin by cyclic AMP-dependent protein
kinase stabilizes β-catenin through inhibition of its
ubiquitination. Mol Cell. 25:9063–9072. 2005.
|
|
30.
|
McDonald JM, Dunlap S, Cogdell D, et al:
The SHREW1 gene, frequently deleted in oligodendrogliomas,
functions to inhibit cell adhesion and migration. Cancer Biol Ther.
5:300–304. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Schreiner A, Ruonala M, Jakob V, et al:
Junction protein shrew-1 influences cell invasion and interacts
with invasion promoting protein CD147. Mol Biol Cell. 18:1272–1281.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Cogdell D, Chung W, Liu Y, McDonald JM,
Aldape K, Issa JP, Fuller GN and Zhang W: Tumor-associated
methylation of the putative tumor suppressor AJAP1 gene and
association between decreased AJAP1 expression and shorter survival
in patients with glioma. Chin J Cancer. 30:247–253. 2011.
View Article : Google Scholar
|
|
33.
|
Jarskog LF, Selinger ES, Lieberman JA and
Gilmore JH: Apoptotic proteins in the temporal cortex in
schizophrenia: high bax/bcl-2 ratio without caspase-3 activation.
Am J Psychiatry. 161:109–115. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Ryan KM, Phillips AC and Vousden KH:
Regulation and function of the p53 tumor suppressor protein. Curr
Opin Cell Biol. 13:332–337. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Kaina B and Christmann M: DNA repair in
resistance to alkylating anticancer drugs. Int J Clin Pharmacol
Ther. 40:354–367. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Bredel M, Bredel C, Juric D, et al: Tumor
necrosis factor-alpha induced protein 3 as a putative regulator of
nuclear factorkappaB- mediated resistance to O6-alkylating agents
in human glioblastoma. J Clin Oncol. 24:274–287. 2006. View Article : Google Scholar
|
|
37.
|
Prokopenko O and Mirochnitchenko O:
Ischemia-reperfusion-inducible protein modulates cell sensitivity
to anticancer drugs by regulating activity of efflux transporter.
Am J Physiol Cell Physiol. 296:1086–1097. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Chekhun VF, Lukyanova NY, Kovalchuk, et
al: Epigenetic profiling of multidrug-resistant human MCF-7 breast
adenocarcinoma cells reveals novel hyper- and hypomethylated
targets. Mol Cancer Ther. 6:1089–1098. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Roberti A, Sala DL and Cinti C: Multiple
genetic and epigenetic interacting mechanisms contribute to
clonally selection of drug-resistant tumors: current views and new
therapeutic prospective. J Cell Physiol. 207:571–581. 2006.
View Article : Google Scholar
|
|
40.
|
Duan Z, Duan Y, Lamendola DE, Yusuf RZ, et
al: Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin
resistant human cancer cell lines. Clin Cancer Res. 9:2778–2785.
2003.PubMed/NCBI
|
|
41.
|
Weeraratne SD, Amani V, Neiss A, et al:
MiR-34a confers chemosensitivity through modulation of MAGE-A and
p53 in medulloblastoma. Neuro Oncol. 13:165–175. 2011. View Article : Google Scholar : PubMed/NCBI
|
